High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors
Authors:
Open Access
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literatureCancer, 2017
- Nanomaterials in Targeting Cancer Stem Cells for Cancer TherapyFrontiers in Pharmacology, 2017
- Immune-Related Adverse Events Associated with Immune Checkpoint InhibitorsBioDrugs, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperAnnals of Oncology, 2015
- Obesity and Cancer Immunotherapy ToxicityImmunotherapy, 2015
- Diagnosis and classification of drug-induced autoimmunity (DIA)Journal of Autoimmunity, 2014
- Association between the human immune response and body mass indexHuman Immunology, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008